A Randomized, Double-blind, Placebo-Controlled Trial of Pentoxifylline for the Treatment of Recurrent Aphthous Stomatitis

Thornhill, Martin H.; Baccaglini, Lorena; Theaker, E. D.; Pemberton, M. N.

doi:10.1001/archderm.143.4.463

Cited by 62 publications

(30 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[29303132] These beneficial effects may be due to anti-TNF-α properties of pentoxifylline as well as correction of impaired erythrocyte deformability, which has been shown to be decreased in active Behçet disease patients in comparison with healthy control subjects. [33]…”

Section: Clinical Applications In Dermatologymentioning

confidence: 99%

Pentoxifylline and its applications in dermatology

Hassan

Dorjay

Anwar

2014

Indian Dermatol Online J

View full text Add to dashboard Cite

Pentoxifylline is a methyl-xanthine derivative with many anti inflammatory effects. Pentoxifylline has been found to be effective for many dermatological as well as non-dermatological conditions. It has been used both as primary drug as well as adjuvant and is a safe and relatively cost-effective alternative drug. In this article, we review the literature and highlight various important aspects of pentoxifylline.

show abstract

Section: Clinical Applications In Dermatologymentioning

confidence: 99%

Pentoxifylline and its applications in dermatology

Hassan

Dorjay

Anwar

2014

Indian Dermatol Online J

View full text Add to dashboard Cite

show abstract

“…[7][8][9] In particular, anti-inflammatory and immunomodulatory agents such as clofazimine, thalidomide, pentoxifylline, colchicine, levamisole, azathioprine, amlexanox, and steroids have been administered with varying clinical benefits. [10][11][12][13][14][15][16][17][18][19][20] Cyclosporine A (CsA) is a potent immunosuppressive agent that interferes with both B-and T-cell activation. It is widely used to prevent organ transplant rejection and in the treatment of various systemic and local immune diseases.…”

Section: Introductionmentioning

confidence: 99%

A new approach to the treatment of recurrent aphthous stomatitis with bioadhesive gels containing cyclosporine A solid lipid nanoparticles: in vivo/in vitro examinations

Karavana¹,

Gökçe²,

Rençber³

et al. 2012

IJN

View full text Add to dashboard Cite

Aim:To develop a suitable buccal bioadhesive gel formulation containing cyclosporine A solid lipid nanoparticles (CsA SLNs) for the treatment of recurrent aphthous stomatitis. Methods: The suitability of the prepared formulations for buccal application was assessed by means of rheological studies, textural profile analysis, and ex vivo drug-release studies. Plastic flows, typical gel-like spectra, and suitable mechanical properties were obtained from prepared formulations. The retention time was explored in in vivo distribution studies and the effect of the gel containing CsA SLNs on the healing of oral mucosal ulceration was investigated in an animal model. In vivo distribution studies are a very important indicator of the retention time of formulations at the application site. Results: Distribution studies showed that 64.76% ± 8.35% of the formulation coded "F8+SLN" remained on the buccal mucosa 6 hours after application. For the second part of the in vivo experiments, 36 rabbits were separated into three groups: the first group was treated with the gel formulation without the active agent; the second group with the gel formulation containing CsA SLNs; and the third group, used as the control group, received no treatment. Wound healing was established by scoring of the rate of wound healing on Days 3, 6, 9, and 12. Histological observations were made on the same days as the scoring studies. The bioadhesive gel formulation that included CsA SLNs increased the rate of mucosal repair significantly. Conclusion: This study has shown that the bioadhesive gel formulation containing CsA SLNs reported here is a promising candidate for the topical treatment of recurrent aphthous stomatitis.

show abstract

“…Pentoxifylline has been used in randomized controlled trials for the treatment of recurrent stomatitis [14]. This is the first report to show improvement of anterior ocular involvement with pentoxifylline.…”

Section: Discussionmentioning

confidence: 93%

Pentoxifylline for the treatment of anterior uveitis in Behcet’s disease: possible alternative for TNF blockers

Appenzeller

Hazel

2009

Rheumatol Int

View full text Add to dashboard Cite

Behcet's disease is an inflammatory disorder of unknown cause, characterized by recurrent oral aphthous ulcers, genital ulcers, uveitis, and skin lesions. All these common manifestations are self-limiting except for the ocular attacks. The objective of the present study is to report the efficacy of pentoxifylline for ocular involvement in Behcet's disease. We report a patient with ocular involvement secondary to Behcet's disease which was corticosteroid dependent and refractory to azathioprine treatment. Pentoxifylline was added with amelioration of inflammation. Pentoxifylline may be a useful treatment option in patients with Behcet's disease, where other immunosuppressives have failed or are contra-indicated.

show abstract

A Randomized, Double-blind, Placebo-Controlled Trial of Pentoxifylline for the Treatment of Recurrent Aphthous Stomatitis

Cited by 62 publications

References 57 publications

Pentoxifylline and its applications in dermatology

Pentoxifylline and its applications in dermatology

A new approach to the treatment of recurrent aphthous stomatitis with bioadhesive gels containing cyclosporine A solid lipid nanoparticles: in vivo/in vitro examinations

Pentoxifylline for the treatment of anterior uveitis in Behcet’s disease: possible alternative for TNF blockers

Contact Info

Product

Resources

About